Shares of Gilead Sciences Inc. GILD inched 0.06% higher to $83.99 Monday, on what proved to be an all-around great trading ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Amidst a resurgence of COVID-19 cases across the United States, pharmaceutical company Gilead Sciences, Inc. has announced a voluntary recall of its antiviral drug Veklury, commonly known as ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer c ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

The manufacturer says the drug is indicated for the treatment of Covid-19 in adults and children, but an unexpected presence ...